AdvaMed Doubled Its Lobbying Spending Over Past Year
Having won repeal of the device tax in late 2019, the group now focuses on CARES Act, user-fee funding
Medtech industry trade group AdvaMed spent more than $2m to help shape US congressional bills in the first quarter of 2020 – more than double what it spent to influence the course of legislation in the first quarter of 2019. Check out our in-depth analysis here.
You may also be interested in...
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
The FDA’s device center is getting a 2% boost after President Trump on 20 December signed off on all appropriations bills for fiscal year 2020.
Under changes announced on 9 October by the US Health and Human Services Office of Inspector General (HHS OIG) and the Centers for Medicare and Medicaid Services (CMS), new so-called "safe harbors" to the anti-kickback statute and planned changes to the physician self-referral statute (Stark Law) would shelter health-care providers – including device-makers – who enter into value-based care arrangements for services paid for by Medicare. Such changes have been promoted by medtech firms.